



Ventilator-Associated Pneumonia Prevention



Basics of Infection Prevention
2-Day Mini-Course
October-November 2011

Objectives

- Review the epidemiology of VAP definitions and the impact in the ICU
- Explore causes and mechanisms of VAP, focusing on modifiable factors
- Discuss evidence-based VAP prevention strategies
- Describe surveillance of VAP and problems associated with definitions



Ventilator Associated Pneumonia (VAP)

- VAP is pneumonia that occurs in patients intubated and on mechanical ventilation
 - or intubated/ventilated within 48 hours prior to pneumonia onset
- 15% - 50% patients with VAP die
 - varies with patient population and organism type
- Highest VAP mortality occurs inpatients with
 - severe illness **and**
 - infection with nonfermentative Gram negative bacilli e.g. *Acinetobacter* sp, *Burkholderia* sp., etc.
- Increases length of stay >6 ICU days
 - Cost \$10,000 - \$40,000

Etiology of VAP

Early onset VAP

- Occurs in first 4 days of hospitalization
- More likely to be caused by *Moraxella catarrhalis*, *H. influenzae*, or *S. pneumoniae*


Late onset VAP:

- Occurs 5 or more days into hospitalization
- Often caused by Gram-negative bacilli, or *S. aureus* (including MRSA), yeasts, fungi, *legionellae* and *Pneumocystis carinii*

Pathogenesis VAP Development


Results from

- Aspiration of secretions
- Colonization of aerodigestive tract
- Contaminated respiratory / other medical equipment




VAP Pathogens

- *Staphylococcus aureus* - 24.4%
- *Pseudomonas aeruginosa* - 16.3%
- *Enterobacter spp* - 8.4%
- *Acinetobacter baumannii* - 8.4%
- *Klebsiella pneumoniae* - 7.5%
- *Escherichia coli* - 4.6%
- *Candida spp* - 2.7%
- *Klebsiella oxytoca* - 2.2%
- *Coagulase-negative staphylococci* - 1.3%



Diagnosis of Pneumonia



Pneumonia has rapid onset and progression, but does not resolve quickly

X-ray changes related to pneumonia can persist for several weeks

Fast resolution of x-ray changes usually suggest a non-infectious process

VAP Prevention

Issue: **Aspiration of secretions**

- Maintain elevation of head of bed (HOB) (30-45 degrees)
- Avoid gastric over-distention
- Avoid unplanned extubation/reintubation
- Use cuffed endotracheal tube with in-line or subglottic suctioning

Prevention of VAP

Issue: **Aspiration of secretions** (continued)

- Positioning
 - Semi-recumbent position (head of bed 30°-45°) unless contraindicated
 - Place reminders at HOB or on posters in room
 - Add HOB to daily goal list/ ICU record
 - Tape 45° goal on bed for visual reminder
 - Give staff feedback on compliance
- Encourage early mobilization of patients with physical/occupational therapy



VAP Prevention

Issue: **Aspiration of secretions** (continued)

- Reduce duration of ventilation
 - Conduct “sedation vacations”
 - Assess readiness to wean from vent daily
 - Conduct spontaneous breathing trials



VAP Prevention

Issue: **Colonization of aerodigestive tract**

- Orotracheal intubation is preferred to nasotracheal intubation
 - Sinusitis may increase VAP risk
- Avoid acid suppressive therapy for patients not at high risk for stress ulcer/stress gastritis
 - May increase colonization of aerodigestive tract with pathogens
- Perform regular oral care with an antiseptic agent



Prevention of VAP Development

Issue: **Colonization of aerodigestive tract -2**

- Endotracheal Tube (ETT)
 - Use cuffed ETT with inline or subglottic suctioning to minimize secretions above cuff, and prevent contamination from entering lower airway
- Use non-invasive methods when possible (i.e., CPAP, BiPap)
- Use orotracheal ventilation (nasotracheal ventilation may cause sinusitis, increasing bacteria colonization)



Prevention of VAP Development

Issue: **Colonization of aerodigestive tract - 3**

- Reduce bacterial colonization
 - Good hand hygiene
 - Use gloves for contact with respiratory secretions/contaminated objects; follow with hand hygiene
 - Educate about potential contamination of ETT from mouth, hands, other infected sites and environment
 - Regular mouth care with an antiseptic



Prevention of VAP Development

Issue: **Use of contaminated equipment**

- Use sterile H2O to rinse reusable respiratory equipment
- Remove condensate from ventilatory circuits
- Change ventilatory circuit only when malfunctioning or visibly soiled
- Store and disinfect respiratory equipment effectively



Challenges in VAP Prevention

- Pre-existing conditions:
 - Head trauma
 - Coma
 - Nutritional deficiencies
 - Immunocompromise
 - Multi organ system failure
 - Acidosis
 - Comorbidities
 - History of smoking or pulmonary disease



VAP Prevention

- Leadership, staffing, informatics and education are essential to VAP reduction programs
- VAP prevention teams must be multidisciplinary, including
 - Senior management
 - MD / RN clinical champion
 - Frontline staff



Identifying VAP

- Follow NHSN protocols for surveillance
- Work with ICU and respiratory therapy staff to develop process for alerting to possible VAP
- Evaluate ventilated patients
 - Positive cultures
 - Chest films (X-ray, MRI, CT)
 - Temperature chart/log
 - Pharmacy reports of antimicrobial use
 - Change in respiratory secretions



VAP Prevention Objectives

- Health and Human Services (HHS) HAI Prevention Action Plan, 2009
 - No valid outcome or process metrics have been identified for VAP

<http://www.hhs.gov/ash/initiatives/hai/prevtargets.html>



VAP Prevention Process Measures

Consider monitoring

- Compliance with hand hygiene
- Compliance with daily sedation vacation/interruption and assessment of readiness to wean
- Compliance with regular antiseptic oral care
- Compliance with semi-recumbent position of all eligible patients

VAP Prevention Outcome Measures

$$\frac{\text{\# Patients with VAP}}{\text{Total \# of ventilated patients}} \times 100$$

- Crude, unadjusted rate
- Not for inter-hospital or between-unit comparisons

$$\frac{\text{\# VAP}}{\text{Total \# of ventilator days}} \times 1000$$

- Incidence-density rate
- Accounts for differences in exposure risk; can be used for rate comparison to similar patient populations stratification

VAP Surveillance

- VAP case finding is complex
- Despite common definition, variability exists between reviewers
- CDC currently evaluating new definition system



NHSN Pneumonia Definition


VAP is HAI pneumonia occurring in ventilated patient (or extubated within previous 48 hours)

Surveillance definition can be met by 3 different criteria

- Clinically defined pneumonia (PNU1)
- Pneumonia with specific laboratory findings (PNU2)
- Pneumonia in immunocompromised patients (PNU3)



Figure 1: Pneumonia Flow Diagram



NHSN pneumonia surveillance definition algorithm (all ages)


IMPORTANT: As you go through the following set of slides, do not get caught up in definition and interpretation problems (we know there are many)

At your facility, decide how the definition will be interpreted and applied, then be consistent over time!

NHSN Pneumonia Definition Algorithm

Positive chest X-rays findings required to start

- new or progressive and persistent infiltrates, consolidation or cavitation on one or more serial x-rays
- if patient has underlying cardiac or pulmonary disease, 2 or more serial x-rays necessary




NHSN Pneumonia Definition Algorithm

Chest X-rays: the following descriptions may be indicative of pneumonia:

- Infiltration
- Consolidation
- Cavitation
- Focal opacification
- Patchy density
- Air space disease

Or


- Pneumatocele in infants (< 1 year age)



NHSN Pneumonia Definition Algorithm


Clinically defined pneumonia (PNU1)

- Definition can be met if +chest x-rays and signs/ symptoms meet criteria
- No laboratory data required



NHSN Pneumonia Definition Algorithm

Third part of the algorithm
addresses laboratory findings
for pneumonia



Criteria can be met in two ways:

1. Pneumonia with common bacterial or filamentous fungal pathogens **and** specific lab findings

- X-ray, signs & symptoms and lab data criteria must be met




NHSN Pneumonia Definition Algorithm

PNU2 (continued)

2. Pneumonia with viral, Legionella, Chlamydia, Mycoplasma, and other uncommon pathogens and specific lab findings

- X-ray, signs /symptoms and lab data criteria must be met



NHSN Pneumonia Definition Algorithm

Pneumonia in immunocompromised patients (PNU3)

- Patient must meet CDC criteria for being immunocompromised
- X-ray, signs /symptoms and lab data criteria must be met, as indicated







Figure 3: Pneumonia Flow Diagram, Alternative Criteria for Infants and Children



Additional algorithm for clinically-defined pneumonia (PNU1) in infants and children

References for VAP Prevention and Bundles

- Institute for Healthcare Improvement (IHI):
 - <http://www.ihl.org/knowledge/Pages/Changes/ImplementtheVentilatorBundle.aspx>
- Agency for Healthcare Research and Quality (AHRQ):
 - <http://www.innovations.ahrq.gov/content.aspx?id=2178>
- VAP Getting Started Kit: Safer Healthcare Now (Canada)
 - <http://www.saferhealthcarenow.ca/EN/Interventions/VAP/Documents/VAP%20One%20Pager.pdf>



References and Resources

- Coffin, S, et al. Strategies to Prevent Ventilator-Associated Pneumonia in Acute Care Hospitals. *Infect Control Hosp Epidemiol* 2008; 29:S31-S40.
- Greene LR, Sposato K, Farber MR, Fulton TM, Garcia RA. (2009). Guide to the Elimination of Ventilator – Associated Pneumonia. Washington, D.C.: APIC.
- Greene LR, Sposato K, Farber MR, Fulton TM, Garcia RA. Guide to the Elimination of Ventilator – Associated Pneumonia, 2009. APIC. 2009.
- Hidron AI, et.al., *Infect Control Hosp Epidemiol* 2008;29:996-1011
- Magill, SS. (2010). Surveillance for ventilator-associated pneumonia at CDC: Current Approach, Challenges, and Future Directions. Retrieved from lecture notes online website: <http://www.hhs.gov/ash/initiatives/hai/Events/progresstoward-day2-magill.pdf>

Questions?

For more information, please contact any
HAI Liaison Team member.

Thank you

